Every three months we review the new research and the regulatory changes affecting what we sell, and publish what we found. Including the quarters where the answer is nothing.
The commitment
We review this quarterly and publish an entry every time, whether or not anything material turned up. Where a finding changes an ingredient’s grade, the grade moves and this log says so. Entries are never edited after publication — if we get something wrong, the correction appears as a new entry with its own date, so the record of having been wrong stays visible.
Entries
Newest first.
4 November 2026
Femme Flora vitamin D3 and vegan declaration received
What it foundNothing in the research changed. This entry records a fact about the product so that the pages on this Hub match it. Our manufacturer has given us a signed, stamped written declaration that Femme Flora is vegan. It confirms that the vitamin D3 is from lichen, that the capsule shell is HPMC (a plant-derived material) and that the cultures are grown on animal-free media. We received it on 4 November 2026. When we published the Femme Flora pages on 2 November we said this declaration was due. The declaration names our manufacturer, so we hold it on file and do not publish it.
Grade impactNone. The grades describe the ingredients, not a batch.
2 November 2026
Femme Flora pages published
Seven new pages: live cultures, xylo-oligosaccharides, riboflavin, niacin, biotin, vitamin D3 and the Femme Flora overview. The ingredients index now covers both products. Before publishing we re-checked every figure against the final Femme Flora formulation (13 October 2026), updated the xylo-oligosaccharides page now the product is made, and removed three references we could not verify from the live cultures page.
29 October 2026
Our formula, and how it differs from earlier batches
What it foundNothing in the research changed. This entry records a fact about the product so that the pages on this Hub match it. Belle Balance’s current formula contains myo-inositol only. Earlier batches included D-chiro; the current formula doesn’t.
Does this change anything for us?Yes, on the page. Every figure on the Belle Balance pages describes the current formula, per 8g sachet.
Grade impactNone. The grades describe the ingredients, not a batch.
29 October 2026
This log opens
What it foundNothing yet. This is the first entry, written as the Research Hub went live.
Does this change anything for us?No. It commits us to something instead. From now on we review the sources listed below every three months and publish what we find — a new trial, a systematic review, a change to what may lawfully be claimed, or a safety signal. If a quarter passes and nothing material turns up, that gets an entry too, because a log that only appears when there is good news is not a log.
The first quarterly review falls in January 2027, and every three months after that.
Grade impactNone. The grades published across the Research Hub today are the starting position.
8 October 2026
Our shatavari now has a specification
What it foundOur shatavari page said our extract was not standardised to a stated marker content, and that we had asked our manufacturer for one. They have now answered. It is a root extract standardised to at least 10.0% total shatavarins (shatavarin IV at least 5.0%) and at least 20.0% total steroidal saponins. It is a generic extract, not a named or branded one.
Does this change anything for us?Yes, on the page. The shatavari page, the index and our Health Claims page have been updated. The figures are the manufacturer’s own and have not been independently tested.
Grade impactNone. Shatavari stays at C. The reason for C has changed: it used to be that we had no specification, and now it is that ours is a generic extract.
What gets an entry
Published here rather than kept internally, because a rule nobody can see is editing rather than a standard.
Yes
Any human trial on an ingredient we use
Any human trial on the same species or substance, even where it does not involve our material
Any systematic review or meta-analysis
Any regulatory change — a claim added or withdrawn, a change to the on-hold botanical list, a ruling in this category
Any safety signal
No
Laboratory and animal studies
Narrative reviews carrying no new data
One exception. Where no human data exists for an ingredient at all, we say so explicitly rather than filling the gap with weaker evidence.
What we monitor
The actual search terms, so you can run them yourself.
Belle Balance
myo-inositol · myo-inositol randomised trial · magnesium glycinate · Rhodiola rosea clinical · Asparagus racemosus · cranberry proanthocyanidin
Regulatory
GB Nutrition and Health Claims Register changes · DHSC Article 13.1 on-hold botanical list · ASA and CAP rulings in food supplements · FSA guidance affecting supplement labelling
The rules this log runs on
Entries are never edited after publication. Corrections are appended as new entries. A log that can be quietly rewritten is not a log.
Findings that go against us get published. If a study undermines an ingredient we use, it gets an entry and the grade moves. That is the entire reason this is worth reading.
The cadence is stated and kept. Quarterly. Four entries a year, published whether or not anything material was found.
Regulatory change counts as a finding. A claim withdrawn from the register changes a label; a new trial on somebody else’s product usually would not. The first is more consequential to you and easier to track.
Choosing a selection results in a full page refresh.